News - OBI Pharma 台灣浩鼎

2018.Apr.19

未分類

Corporate

OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

2018.Jan.17

未分類

Corporate

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

2017.Dec.22

未分類

Corporate

OBI Pharma announces participation at the 36th J.P. Morgan Annual Healthcare Conference in San Francisco from January 8-10, 2018.

2017.Oct.30

未分類

Corporate

OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2017.Oct.24

未分類

Corporate

OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2017.Jul.11

未分類

Corporate

Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)

2017.Jun.01

未分類

Corporate

OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals

2017.Jan.25

未分類

Corporate

China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study

2017.Jan.20

未分類

Corporate

OBI Pharma holds EOP2 meeting with US FDA

2017.Jan.10

未分類

Corporate

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.

Announcements

Latest announcements

Events

Latest events